@article {{\'S}RODA-POMIANEK727, author = {KAMILA {\'S}RODA-POMIANEK and KRYSTYNA MICHALAK and ANNA PALKO-{\L}ABUZ and ANNA URYGA and BERENIKA SZCZ{\k E}{\'S}NIAK-SI{\k E}GA and OLGA WESO{\L}OWSKA}, title = {Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and Cytotoxic Activity of Oxicam Derivatives in Doxorubicin-resistant Colon Cancer Cells}, volume = {39}, number = {2}, pages = {727--734}, year = {2019}, doi = {10.21873/anticanres.13169}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Incidence of cancer is still increasing. Chemotherapy is often unsuccessful; moreover, anticancer drugs cause serious side-effects. It is necessary to develop effective agents for combination therapies that would increase antitumor effects of treatment and reduce its side-effects. Materials and Methods: Anticancer activity of oxicam derivatives (PR17 and PR18) alone and in combination with simvastatin on doxorubicin-resistant colon cancer cells was studied. Apoptosis was investigated via caspase-3 activation assay as well as via western blot analysis of expression of apoptotic components, B-cell lymphoma 2 protein (BCL2) and BCL2-associated X protein (BAX). Expression and activity of cyclo-oxygenase-2 (COX2) was also assessed. Results: Oxicam derivatives induced apoptosis through a caspase-3-dependent pathway, up-regulated BAX expression, and down-regulated BCL2 expression. Additionally, oxicam derivatives reduced expression and activity of COX2. Effect of oxicam derivatives on these processes was strongly potentiated by simvastatin. Conclusion: Oxicam derivatives at low concentrations effectively inhibit growth of cancer cells after co-administration with simvastatin.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/39/2/727}, eprint = {https://ar.iiarjournals.org/content/39/2/727.full.pdf}, journal = {Anticancer Research} }